DDInter1381 DDInter1376
Paliperidone is the primary active metabolite of risperidone. The mechanism of action is unknown but it is likely to act via a similar pathway to risperidone. It has been proposed that the drug's therapeutic activity in schizophrenia is mediated through a combination of central dopamine Type 2 (D2) and serotonin Type 2 (5HT2A) receptor antagonism. Paliperidone is also active as an antagonist at alpha 1 and alpha 2 adrenergic receptors and H1 histaminergic receptors, which may explain some of the other effects of the drug. Paliperidone was approved by the FDA for treatment of schizophrenia on December 20, 2006. It is available as an extended-release tablet, a once-monthly intramuscular injection, an every-three-month intramuscular injection, and a twice-yearly gluteal injection.[L16168,L37744,L4137,L37749]
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Paliperidone {u} (Compound) resembles {v} (Compound) Risperidone
Paliperidone {u} (Compound) binds {v} (Gene) DRD2
Paliperidone {u} (Compound) palliates {v} (Disease) schizophrenia
Paliperidone {u} (Compound) causes {v} (Side Effect) Skin discolouration
Paliperidone {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Paliperidone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Eribulin
Paliperidone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Glipizide
Paliperidone {u} may lead to a major life threatening interaction when taken with {v} Metoclopramide
Paliperidone {u} may lead to a major life threatening interaction when taken with {v} Vemurafenib
Paliperidone (Compound) resembles Risperidone (Compound)
Paliperidone (Compound) binds DRD2 (Gene)
Paliperidone (Compound) palliates schizophrenia (Disease)
Paliperidone (Compound) causes Skin discolouration (Side Effect)
Paliperidone may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Paliperidone may cause a moderate interaction that could exacerbate diseases when taken with Eribulin
Paliperidone may cause a moderate interaction that could exacerbate diseases when taken with Glipizide
Paliperidone may lead to a major life threatening interaction when taken with Metoclopramide
Paliperidone may lead to a major life threatening interaction when taken with Vemurafenib